These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23355631)

  • 1. Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard.
    Vanderstichele HM; Shaw L; Vandijck M; Jeromin A; Zetterberg H; Blennow K; Teunissen C; Engelborghs S
    Clin Chem; 2013 Apr; 59(4):710-2. PubMed ID: 23355631
    [No Abstract]   [Full Text] [Related]  

  • 2. Cerebrospinal fluid opens a window on Alzheimer disease.
    Galasko D
    Arch Neurol; 1999 Jun; 56(6):655-6. PubMed ID: 10369301
    [No Abstract]   [Full Text] [Related]  

  • 3. LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia.
    Le Bastard N; Van Buggenhout M; De Leenheir E; Martin JJ; De Deyn PP; Engelborghs S
    J Gerontol A Biol Sci Med Sci; 2007 Aug; 62(8):923-4; author reply 924-5. PubMed ID: 17702886
    [No Abstract]   [Full Text] [Related]  

  • 4. Round robin test on quantification of amyloid-β 1-42 in cerebrospinal fluid by mass spectrometry.
    Pannee J; Gobom J; Shaw LM; Korecka M; Chambers EE; Lame M; Jenkins R; Mylott W; Carrillo MC; Zegers I; Zetterberg H; Blennow K; Portelius E
    Alzheimers Dement; 2016 Jan; 12(1):55-9. PubMed ID: 26206625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?
    Lehmann S; Gabelle A; Paquet C
    Alzheimers Dement; 2015 Sep; 11(9):1125-6. PubMed ID: 25457432
    [No Abstract]   [Full Text] [Related]  

  • 6. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
    Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
    JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment.
    Dean RA; Shaw LM
    Clin Chem; 2010 Jan; 56(1):7-9. PubMed ID: 19926774
    [No Abstract]   [Full Text] [Related]  

  • 8. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.
    Mattsson N; Zegers I; Andreasson U; Bjerke M; Blankenstein MA; Bowser R; Carrillo MC; Gobom J; Heath T; Jenkins R; Jeromin A; Kaplow J; Kidd D; Laterza OF; Lockhart A; Lunn MP; Martone RL; Mills K; Pannee J; Ratcliffe M; Shaw LM; Simon AJ; Soares H; Teunissen CE; Verbeek MM; Umek RM; Vanderstichele H; Zetterberg H; Blennow K; Portelius E
    Biomark Med; 2012 Aug; 6(4):409-17. PubMed ID: 22917143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid.
    Schipke CG; Prokop S; Heppner FL; Heuser I; Peters O
    Dement Geriatr Cogn Disord; 2011; 31(2):139-45. PubMed ID: 21304219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort.
    Klafki HW; Hafermann H; Bauer C; Haussmann U; Kraus I; Schuchhardt J; Muck S; Scherbaum N; Wiltfang J
    J Alzheimers Dis; 2016 Sep; 54(2):691-705. PubMed ID: 27567847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
    Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE
    Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays.
    Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J
    J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease.
    Mehta PD; Pirttila T
    Neurodegener Dis; 2005; 2(5):242-5. PubMed ID: 16909004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.
    Niemantsverdriet E; Goossens J; Struyfs H; Martin JJ; Goeman J; De Deyn PP; Vanderstichele H; Engelborghs S
    J Alzheimers Dis; 2016; 51(1):97-106. PubMed ID: 26836187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF α-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid β in humans.
    Spies PE; Slats D; Rikkert MG; Tseng J; Claassen JA; Verbeek MM
    Neurosci Lett; 2011 Oct; 504(3):336-8. PubMed ID: 22001363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
    Marksteiner J; Hinterhuber H; Humpel C
    Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A screening UHPLC-MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species.
    Dillen L; Cools W; Vereyken L; Timmerman P
    Bioanalysis; 2011 Jan; 3(1):45-55. PubMed ID: 21175366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.
    Riemenschneider M; Lautenschlager N; Wagenpfeil S; Diehl J; Drzezga A; Kurz A
    Arch Neurol; 2002 Nov; 59(11):1729-34. PubMed ID: 12433260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer disease: chaperone protein clusterin is involved in amyloid-β-associated entorhinal atrophy in early AD.
    Malkki H
    Nat Rev Neurol; 2014 Feb; 10(2):60. PubMed ID: 24445801
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.